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How mutant p53 empowers Foxh1
fostering leukaemogenesis?
Ivano Amelio 1
This year the biomedical research community is cele-
brating the 40th anniversary of the discovery of the most
frequently mutated gene across all human cancer1. p53
was firstly identified in 1979; for a decade, its function was
associated with its oncogenic properties, leading to the
conclusion that p53 was a powerful oncogene2–4. Only
later, the confusion was clarified: most of the researchers
were unaware that they were in fact studying its mutant
forms5,6. 40 years later, whether p53 mutants are effec-
tively functioning as oncogenes and whether their gain-of-
function effects are contributing to the pathogenesis of
cancer remains largely controversial7–9 (Fig. 1). But how
does mutant p53 gain its oncogenic properties? Scott
Lowe’s group recently reported important observations in
support of a major contribution of p53 mutants to mye-
loid leukaemia pathogenesis10.
In acute myeloid leukaemia (AML) TP53 mutations are
mainly associated with the subtype known as complex
karyotype AML (CK-AML). CK-AML is a lethal disease
(less than 2%, 5-year survival) characterised by the presence
of several cytogenetic abnormalities. Lowe and colleagues’
work formally demonstrates that expression of p53R172H
(the mouse orthologue of the human R175H mutation)
accelerates the onset of haematological malignancies
beyond the effects of p53 deficiency10. Consistent with what
has previously been reported, mice harbouring p53R172H
succumb from thymic lymphomas faster than mice com-
pletely lacking p53 expression. To assess the impact of
p53R172H in the clinically relevant context of AML, the
authors transplanted bone marrow cells from Mx1-Cre;
p53R172H/F and Mx1-Cre;p53F/F mice into thymectomized
recipient mice. The p53R172H/- mice succumbed to the
disease faster than their p53-null counterparts. Importantly,
depletion of p53R172 by an inducible shRNA system in AML
cells led to differentiation and apoptosis, indicating that
AML cells expressing p53R172H acquire a molecular
dependency on mutant p53. Hence, p53R172 contributes to a
differentiation block that sustains leukemogenesis10. This
set of data therefore supports a gain-of-function effect of
p53R172 in an AML setting.
Lowe’s team observed that the adult bone marrow cells
from p53R172H/Δ mice have significantly higher replating
capacity compared to cells from p53-null mice in a serial
replating experiment performed with limiting dilution
cultures in methylcellulose medium. Consistent with
these findings, competitive transplantation studies using
p53WT/WT, p53Δ/Δ, and p53R172H/Δ bone marrow cells
demonstrated that p53R172H/Δ cells outcompeted wild-
type cells to a greater extent than p53Δ/Δ cells. These
observations establish a role for p53R172H in a pre-
malignant setting in sustaining pathologic self-renewal in
adult hematopoietic cells. Remarkably, the increase in
self-renewal capacity was observed in p53R172H/Δ but not
p53R172H/WT cells, suggesting that loss of the residual WT
allele is a prerequisite10. While overall these data support
a p53R172H gain-of-function effect as they contradict the
long-lasting hypothesis of a dominant negative effect of
p53 mutants on wt p53 (and possibly other p53 family
members). This highlights the complexity of the p53
mutant gain-of-function effects and the corresponding
difficulties in unifying diverse observations.
From a mechanistic standpoint, the authors showed that
p53R172H promotes expression of the Foxh1 transcrip-
tional factor, thus supporting a transcriptional repro-
gramming that sustains the enhanced self-renewal
phenotype of leukaemic cells. This transcriptional sig-
nature was also found to be correlated with p53 mutant
status in human CK-AML. Foxh1 expression was proved
to be necessary and sufficient to sustain the p53R172H-
dependent phenotype. Enforced or reduced expression of
Foxh1 affected hematopoietic cell differentiation and self-
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renewal capacity consistent with the pathological role of
the p53R172H-Foxh1 axis10. Hence, this study demon-
strates that, in this specific context, mutant p53 acts as a
bona fide oncogene that contributes to the pathogenesis
of CK-AML with a mechanism involving Foxh1.
In the wide range of proposed p53 mutant gain-of-
function mechanisms and the highly diverse sets of
observations related to its oncogenic phenotype, this
study establishes proliferative potential and self-renewal
capacity as consistent and relevant aspects in the biology
of mutant p53 gain-of-function. Cancer cells expressing
p53 mutants appear to acquire proliferative benefits that
may substantially exceed the advantage conferred by loss
of the wild-type endogenous p53. However, this simplistic
interpretation of the mutant p53 gain-of-function does
not necessarily explain how cancer cells became depen-
dent on mutant p53 expression, a phenomenon highly
reproducible across many cancer types and characteristic
of several different mutants11. A proliferative advantage
indeed does not fully justify the addiction that cancer cells
display to p53 mutant expression. Despite its important
therapeutic implications, the underlining mechanisms
associated with p53 mutant dependency therefore remain
largely unexplained.
It is also still unclear how mutant p53 is executing its
gain-of-function effects. Is the p53 mutant protein capable
of specifically controlling molecular signalling or is it
randomly altering physiological molecular networks?
p53R172H leukaemic cells express high levels of Foxh1, but
how this occurs remains to be determined. Several tran-
scriptional factors, including SREBPs and HIF-1 have
been shown to be altered in their transcriptional ability by
mutant p5312–14, although it remains unclear how mutant
p53 modifies their function. A fascinating unifying
hypothesis could be that p53 status influences the global
epigenetic landscape thus indirectly influencing the
function of many transcriptional factors.
Additional work, and also careful reanalysis of the
available data, is still required to assess the individual
contribution of gain-of-function and loss-of-function
mutant p53 to cancer pathogenesis. For example, it is
interesting that loss of genomic integrity related to p53
inactivation is observed both in p53-null and p53 mutant
backgrounds12. Genomic instability is a hallmark of
malignant cancers and is crucially associated with the
acquisition of the cellular plasticity that is necessary for
evolution of the malignant disease. In assessing the rela-
tive contribution of the gain-of-function vs. the loss-of-
function mutants, the contribution of any additional p53
mutant property might therefore appear marginal in
comparison with the loss of genomic integrity. However,
the strong selective pressure that leads to acquisition of
missense mutations in the TP53 gene rather than total
gene deletion remains a very important argument in
support of the relevance of the gain-of-function
mutants15.
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Fig. 1 p53 mutational spectrum. a Structural representation of human p53 core domain with hot spot mutation R273H. b Schematic
representation of p53 domains including information on frequencies and types of mutations spanning across the entire human p53 sequence in
acute amyloid leukaemia. Red picks indicate frequency of hotspot mutations; pink bars indicate position and type of missense mutations; purple bars
indicate position and type of in frame deletions; red bars indicate position and type of nonsense mutations. Highest frequency and variety of
mutations is observed in the p53 DNA binding domain. Source: COSMIC mutation database
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